August 29, 2025 — Leads & Copy — Vaxart, Inc. (OTCQX: VXRT) announced it received a decision letter from the Nasdaq Hearings Panel granting the company’s request to effect a plan to regain compliance with the Nasdaq Stock Market’s minimum bid price requirement.
The grant is subject to conditions, including stockholder approval for a reverse stock split by September 5, completing the split by October 6, and demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) by October 17.
At an August 14 hearing, Vaxart’s management outlined the company’s background and compliance plan, highlighting changes to its reverse stock split proposal.
The company continues direct engagement with stockholders and addressed questions during an August 20 virtual fireside chat, with a replay available online.
CEO Steven Lo stated that the Nasdaq listing is crucial and hinges on a successful reverse stock split, urging stockholders to vote in support.
Stockholders with questions can contact Campaign Management at 1-855-264-1527 or info@campaign-mgmt.com.
Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using its proprietary delivery platform, with programs targeting coronavirus, norovirus, influenza, and HPV.
Contact: Matt Steinberg, FINN Partners, IR@vaxart.com, (646) 871-8481
Source: Vaxart
